Is LL-37 found naturally in the human body?

Yes. LL-37 is the only known human cathelicidin peptide — your immune cells, skin, and mucosal surfaces all produce it. Your body ramps up production in response to infection or injury. Research also shows that vitamin D significantly boosts LL-37 levels in immune cells, suggesting a strong nutritional-immune connection. It is being studied as a template for new antimicrobial drugs.

What makes Thymalin different from other immune peptides?

Thymalin comes from the thymus gland, which trains the T-cells that coordinate your immune response. Unlike broad antimicrobial peptides, Thymalin's research focus is on immune regulation and restoration — particularly in aging populations where thymus activity declines. Most of its clinical research has been conducted in Eastern Europe, making it less familiar in Western literature but still scientifically documented.

Why does research dosing vary so much between studies?

Doses in research are shaped by the study model used — cell cultures, animal experiments, and human trials all use different scales. For LL-37, cell studies often use micromolar concentrations, while in vivo models scale up. Thymalin clinical trials have typically used daily injectable doses in the milligram range. Always check which model a dose comes from before drawing comparisons.

Can LL-37 cause harm as well as help?

Research shows LL-37 has a dual nature. At low, physiological concentrations it fights pathogens and helps repair tissue. At higher concentrations it can be toxic to the body's own cells, including bone-forming osteoblasts. This dose-dependent behavior is a key reason why researchers carefully track concentration thresholds — and why dosing charts and research tools are important resources for understanding the published data.

LL-37 vs Thymalin: Research Dosing Comparison

Meet the Two Peptides

Not all peptides are the same. Some fight bacteria. Some tune the immune system. And some do a bit of both — just in completely different ways. LL-37 and Thymalin are two research peptides that often appear in the same conversation, but they belong to different biological families and have been studied for very different reasons.

Let's break them down simply.

What Is LL-37?

LL-37 is a cathelicidin — a type of antimicrobial peptide your body actually makes. It's 37 amino acids long (hence the name). Your skin, lungs, gut, and immune cells all produce it. Think of it as part of your front-line defense system.

Your body boosts LL-37 production when it senses an invader. Interestingly, vitamin D plays a role here — lab research shows that a physiological dose of vitamin D can increase LL-37 protein levels three to four times in immune cells.^[1]

Researchers have studied LL-37 across a wide range of areas:

Fighting bacteria: It disrupts bacterial membranes and breaks up the sticky films — called biofilms — that bacteria hide in. Studies show it can target tough pathogens like Pseudomonas aeruginosa and Staphylococcus aureus.^[5]
Activating platelets: LL-37 has been shown to trigger antimicrobial activity in human platelets — the tiny blood cells usually associated with clotting.^[3]
Immune signaling: It forms complexes with genetic material (like double-stranded RNA) that can amplify immune signals inside cells.^[4]
Heart research: Scientists have explored a direct link between LL-37, inflammation, and heart attack biology.^[2]
Bone and tissue repair: LL-37 promotes new blood vessel growth and helps stem cells migrate — both useful in regenerating bone and gum tissue.^[6]

It's not all upside, though. At high concentrations, LL-37 can be toxic to the body's own cells, including bone-forming osteoblasts.^[1] That dual nature — helpful defender, potential irritant — is why dosing data matters so much in research contexts.

What Is Thymalin?

Thymalin is a thymic peptide — a short peptide originally isolated from the thymus gland. The thymus is the organ responsible for training T-cells, a key part of your adaptive immune system. As people age, the thymus shrinks and becomes less active, which is linked to weakened immunity.

Thymalin has been studied most extensively in Russian and Eastern European clinical research, where it has been explored as a way to restore immune function in elderly populations and support recovery from illness. It works by influencing T-cell maturation and cytokine balance — essentially helping the immune system remember how to coordinate itself.

Quick Comparison: LL-37 vs Thymalin

Origin: LL-37 is made naturally in the human body; Thymalin is derived from thymus tissue extracts.
Primary research focus: LL-37 → antimicrobial defense, inflammation, tissue repair; Thymalin → immune restoration, aging, T-cell support.
Research dose range: LL-37 studies typically use microgram-to-milligram quantities in cell and animal models; Thymalin clinical research has used doses commonly in the range of 5–10 mg per day in short courses.
Evidence base: LL-37 has a large, growing body of cell and molecular research; Thymalin has a more established (though less internationally published) clinical trial record.
Key concern: LL-37 shows dose-dependent cytotoxicity at higher levels^[1]; Thymalin research has generally reported a mild safety profile in older adult populations.
Who studies it: LL-37 is popular in microbiology, immunology, and cardiovascular labs^[2]; Thymalin research is concentrated in gerontology and immunorehabilitation fields.

How to Choose What to Read About

Ask yourself: What biological question interests me most?

If you're curious about how the body fights infection, how antimicrobial peptides work, or how inflammation connects to heart disease — LL-37's research literature is rich and fast-moving. If you're more interested in immune aging, thymus biology, or how peptides might support immune recovery in older adults — Thymalin's clinical data is the more relevant starting point.

Neither peptide is a simple story. Both have nuanced dose-response profiles that are still being worked out in research settings. That's why having accurate, up-to-date dosing charts matters. You can explore published research dose data for both on our dedicated pages, and use our calculator to understand how researchers scale doses across different study models.

The Bottom Line

LL-37 and Thymalin are both peptides with immune-related research profiles — but they operate in different lanes. LL-37 is your body's own antimicrobial multi-tool, studied from bacteria to bones.^[3][4][5][6] Thymalin is a thymus-derived peptide studied for rebuilding immune competence, especially with age. Understanding the difference helps you read the science more clearly — and ask better questions.

Sources

Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. — Biochemical and biophysical research communications, 2024. PMID 38642493.
LL-37: A Direct Link Between Inflammation and Myocardial Infarction. — JACC. Basic to translational science, 2024. PMID 39170953.
LL-37 Triggers Antimicrobial Activity in Human Platelets. — International journal of molecular sciences, 2023. PMID 36769137.
LL-37-dsRNA Complexes Modulate Immune Response via RIG-I in Oral Keratinocytes. — Inflammation, 2023. PMID 36763254.
Antibiofilm properties of cathelicidin LL-37: an in-depth review. — World journal of microbiology & biotechnology, 2023. PMID 36781570.
Regulation of LL-37 in Bone and Periodontium Regeneration. — Life (Basel, Switzerland), 2022. PMID 36294968.

LL-37 vs Thymalin: A Simple Research Comparison Guide